Final Programme - World Heart Federation

industry sAteLLite syMPosiA And WorksHoP ACtivities - evening sessions
Monday, 19 May 2008
seine - gReen Pavillion - 18:00-19:30
Symposium (IS)
Sanofi-aventis
ReshaPing the futuRe in the management of atRial fibRillation
Chairs: John Camm (UNITED KINGDOM), Marcelo Elizari (ARGENTINA)
18:00 Rationale for outcomes studies in atrial fibrillation
Gerald Nacarelli (UNITED STATES)
18:30 Impact of atrial fibrillation in the prognosis of cardiovascular disease
Marcelo Elizari (ARGENTINA)
19:00 ATHENA: a landmark study in atrial fibrillation
John Camm (UNITED KINGDOM)
ganges - gReen Pavillion - 18:00-19:30
Symposium (IS)
Merck Sharp and Dohme
eR niaCin/laRoPiPRant: a neW PaRadigm in ComPRehensive liPid management
Chairs: Pedro Lipszyc (ARGENTINA), Ricardo Horacio Rey (ARGENTINA)
18:00 Epidemiology in Latin America
Ricardo Horacio Rey (ARGENTINA)
18:22 The need for Comprehensive Lipid Management
Anders G. Olsson (SWEDEN)
18:44 New Insights into Niacin Biology
Pedro Lipszyc (ARGENTINA)
19:06 Laropiprant: unlocking the Therapeutic Potential of Niacin
Moriguchi Emilio Hideyuki (BRAZIL)
nile - yelloW Pavillion - 18:00-19:30
Symposium (IS)
GlaxoSmithKline
diabetes, CaRdiovasCulaR disease and thiazelidinediones
Chairs: Isaac Sinay (ARGENTINA), Juan Rosas (MEXICO)
18:00 Diabetes, Metabolic Syndrome & Cardiovascular disease
Álvaro Avezum (BRAZIL)
18:22 Rosiglitazone the most widely studied Oral Antidiabetic Medicine
Isaac Sinay (ARGENTINA)
18:44 Rosiglitazone FDA final statement
Juan Rosas (MEXICO)
19:06 Rosiglitazone Cardiovascular Profile
Nesto Richard W (UNITED STATES)
scientific Programme / 285